Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection
Free accessResearch articleFirst published online August, 2010
Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection
Commercially available prophylactic vaccines containing hepatitis B surface antigen (HBsAg), which are used to prevent HBV infections, are not as effective as a therapeutic immune modulator for treating patients with chronic hepatitis B (CHB). In this study, the immunogenicity of dendritic cells (DC) loaded with both HBsAg and hepatitis B core antigen (HBcAg) was tested in HBV transgenic mice (TM; 1.2HB-BS10) in vivo and in patients with CHB in vitro.
Methods
Spleen DC from HBV TM were cultured with a vaccine containing both HBsAg and HBcAg to produce HBsAg/HBcAg-pulsed DC. HBV TM were immunized twice at an interval of 4 weeks with HBsAg/HBcAg-pulsed DC and other immune modulators. Antibody titres to HBsAg (anti-HBs) were measured in sera. Antigen-specific T-cells and cytotoxic T-lymphocytes (CTLs) in the spleen and liver were detected by lymphoproliferative and ELISPOT assays, respectively. HBsAg/HBcAg-pulsed human blood DC were cultured with autologous T-cells from CHB patients to assess their antigen-specific immune modulatory capacities.
Results
Significantly higher levels of anti-HBs, HBsAg-specific and HBcAg-specific T-cells and CTLs were detected in the spleen and liver of HBV TM immunized with HBsAg/HBcAg-pulsed DC compared with those immunized with other vaccine formulations (P<0.05). HBsAg/HBcAg-pulsed human blood DC also induced HBsAg- and HBcAg-specific proliferation of autologous T-cells from CHB patients.
Conclusions
The immune modulatory capacities of HBsAg/ HBcAg-pulsed DC in HBV TM in vivo, and in patients with CHB in vitro, inspire optimism about a clinical trial with this cell-based vaccine in patients with CHB.
References
1.
FérirG., KapteinS., NeytsJ., De ClercqE.Antiviral treatment of chronic hepatitis B virus infections; the past, the present and the future.Rev Med Virol2008; 18: 19–34.
2.
ShamliyanT.A., MacDonaldR., ShaukatA.Antiviral therapy for adults with chronic hepatitis B: a systemic review for a National Institutes of Health Consensus Development Conference.Ann Intern Med2009; 150: 111–124.
3.
RehermannB.Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.Semin Liver Dis2007; 27: 152–160.
4.
BoniC., PennaA., OggG.S.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.Hepatology2001; 33: 963–971.
5.
SprengersD., JanssenH.L.Immunomodulatory therapy for chronic hepatitis B virus infection.Fundam Clin Pharmacol2005; 19: 17–26.
6.
PolS., MichelM.L.Therapeutic vaccination in chronic hepatitis B virus carriers.Expert Rev Vaccines2006; 5: 707–716.
7.
OnjiM., AkbarS.M.Dendritic Cell in Clinics.2nd ed.Tokyo: Springer2008.
8.
van der MolenR.G., SprengersD., BindaR.S.Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.Hepatology2004; 40: 738–746.
9.
ChisariF.V., FerrariC.Hepatitis B virus immunopathogenesis.Annu Rev Immunol1995; 13: 29–60.
10.
JiangW.Z., FanY., LiuX.Therapeutic potential of dendritic cell-based immunization against HBV transgenic mice.Antiviral Res2008; 77: 50–55.
11.
AkbarS.M., FurukawaS., HasebeA., HoriikeN., MichitakaK., OnjiM.Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.Int J Mol Med2004; 14: 295–299.
12.
ArakiK., MiyazakiJ., HinoO.Expression and replication of hepatitis B virus genome in transgenic mice.Proc Natl Acad Sci U S A1989; 86: 207–211.
13.
NiiyaT., AkbarS.M., YoshidaO.Impaired dendritic cell function resulting from chronic undernutrition disrupts the antigen-specific immune response in mice.J Nutr2007; 137: 671–675.
14.
AkbarS.M., OnjiM., InabaK., YamamuraK., OhtaY.Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cells.Immunology1993; 78: 468–475.
15.
YoshidaO., AkbarF., MiyakeT.Impaired dendritic cell functions because of depletion of natural killer cells disrupt antigen-specific immune responses in mice: restoration of adaptive immunity in natural killer-depleted mice by antigen-pulsed dendritic cell.Clin Exp Immunol2008; 152: 174–181.
16.
AkbarS.M., FurukawaS., YoshidaO., HiasaY., HoriikeN., OnjiM.Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells.J Hepatol2007; 47: 60–66.
17.
AkbarS.M., FurukawaS., NakanishiS., AbeM., HoriikeN., OnjiM.Therapeutic efficacy and decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.J Gastroenterol2005; 40: 157–163.
18.
BetancourtA.A., DelgadoC.A., EstévezZ.C.Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.Int J Infect Dis2007; 11: 394–401.
19.
AkbarS.M., AbeM., MasumotoT., HoriikeN., OnjiM.Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.J Hepatol1999; 30: 755–764.
20.
HasebeA., AkbarS.M., FurukawaS., HoriikeN., OnjiM.Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses.Clin Exp Immunol2005; 139: 35–42.
21.
KeeffeE.B., DieterichD.T., HanS.H.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.Clin Gastroenterol Hepatol2008; 6: 1315–1341.
22.
PolS.Immunotherapy of chronic hepatitis B by anti HBV vaccine.Biomed Pharmacother1995; 49: 105–109.
23.
HoriikeN., AkbarS.M., MichitakaK.In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.J Clin Virol2005; 32: 156–161.
24.
AkbarS.M., YoshidaO., FurukawaS., HiasaY., HoriikeN., OnjiM.Induction of antigen-specific humoral and cellular immune responses by antigen-pulsed dendritic cells in hepatitis B vaccine nonresponders and patients with chronic hepatitis B.58th Annual Meeting of the American Association for the Study of Liver Diseases. 2–6 November 2007, Boston, MA, USA. Abstract 110.
25.
LobainaY., PalenzuelaD., PichardoD., MuzioV., GuillénG., AguilarJ.C.Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen.Mol Immunol2005; 42: 289–294.
26.
VanlandschootP., CaoT., Leroux-RoelsG.The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure.Antiviral Res2003; 60: 67–74.
27.
LeeB.O., TuckerA., FrelinL.Interaction of the hepatitis B core antigen and the innate immune system.J Immunol2009; 182: 6670–6681.
28.
VanlandschootP., Van HoutteF., HoekF., NieuwlandR., Leroux-RoelsG.Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity.J Med Virol2003; 70: 513–519.
29.
AguilarJ.C., LobainaY., MuzioV.Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen.Immunol Cell Biol2004; 82: 539–546.
